BioSpace News Archive

Loki Therapeutics today announced that it has secured seed financing led by Formic Ventures. With this additional funding, Loki has been able to raise a total of $2 million to date.

Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced multiple presentations at the upcoming Association for Research in Otolaryngology (ARO) 45th Annual MidWinter Meeting, to be held virtually during February.

Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today that management will be speaking and participating in several panel and presentation sessions during Phacilitate’s Advanced Therapies Week from January 25-28, 2022 in Miami Beach, FL.

Aeglea BioTherapeutics, Inc. today announced that it will host a Key Opinion Leader (KOL) and Patient Caregiver Webinar on Arginase 1 Deficiency on Thursday, February 3, 2022.

Arcturus Therapeutics Holdings Inc. today announced new data from clinical development programs for ARCT-154 and ARCT-165, its investigational, next-generation, self-amplifying mRNA vaccine candidates targeting variants of concern.

Bio-Rad Laboratories, Inc. will report financial results for the fourth quarter and full year 2021 on Thursday, February 10, 2022, following the close of the market.

ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), today announced clearance of its Clinical Trial Application (CTA) by the regulatory authorities of the Republic of Korea for ORIC-114, a brain penetrant, orally bioavailable, irreversible inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations.

Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), today announced that the first patient has been dosed in its Phase I clinical trial evaluating BMF-219.

Biostage, Inc. announced that it will be hosting a webinar to allow investors to meet its new Interim CEO, David Green.

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (“RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair, and regeneration), today announced that Chinese researchers confirmed the ability of Thymosin beta 4 (Tβ4) to protect corneal stromal cells from damage due to ethanol exposure and significantly promote wound healing.